Dr. Agarwal's Eye Hospital Limited (BOM:526783)
India · Delayed Price · Currency is INR 4,742.70
-89.35 (-1.85%)
At close: Feb 13, 2026
BOM:526783 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 4,507 | 3,972 | 3,193 | 2,681 | 2,012 | 1,398 |
Other Revenue | - | - | - | - | - | 5.17 |
| 4,507 | 3,972 | 3,193 | 2,681 | 2,012 | 1,403 | |
Revenue Growth (YoY) | 19.22% | 24.38% | 19.10% | 33.24% | 43.39% | -20.85% |
Cost of Revenue | 2,498 | 2,260 | 1,868 | 1,576 | 649.3 | 510.69 |
Gross Profit | 2,009 | 1,712 | 1,325 | 1,105 | 1,363 | 892.57 |
Selling, General & Admin | 147.8 | 147.8 | 127.7 | 106.3 | 71.2 | 49.82 |
Other Operating Expenses | 423.1 | 370.4 | 282.4 | 246.1 | 714.8 | 522.15 |
Operating Expenses | 1,016 | 919.9 | 678.3 | 556.5 | 989.9 | 774.38 |
Operating Income | 993.8 | 792.1 | 646.8 | 548.3 | 372.9 | 118.19 |
Interest Expense | -117.3 | -123.6 | -71 | -68 | -61.2 | -61.31 |
Interest & Investment Income | 8.2 | 8.2 | 19.5 | 7.8 | 5.4 | 1.32 |
Currency Exchange Gain (Loss) | - | - | - | -1.1 | -0.1 | -0.08 |
Other Non Operating Income (Expenses) | 0.3 | 5.7 | 12.3 | 4.3 | 3.9 | -0.59 |
EBT Excluding Unusual Items | 885 | 682.4 | 607.6 | 491.3 | 320.9 | 57.53 |
Gain (Loss) on Sale of Investments | 8.8 | 8.8 | - | - | - | - |
Gain (Loss) on Sale of Assets | -1.6 | -1.6 | -2.3 | 0.3 | 2.2 | -0.2 |
Other Unusual Items | 17.4 | 17.4 | 17.2 | 2.4 | - | - |
Pretax Income | 909.6 | 707 | 622.5 | 494 | 323.1 | 57.33 |
Income Tax Expense | 211.1 | 160.5 | 158.9 | 124.8 | 82.1 | 71.71 |
Net Income | 698.5 | 546.5 | 463.6 | 369.2 | 241 | -14.39 |
Net Income to Common | 698.5 | 546.5 | 463.6 | 369.2 | 241 | -14.39 |
Net Income Growth | 35.76% | 17.88% | 25.57% | 53.20% | - | - |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 |
EPS (Basic) | 147.50 | 116.28 | 98.64 | 78.55 | 51.28 | -3.06 |
EPS (Diluted) | 147.50 | 116.28 | 98.64 | 78.55 | 51.28 | -3.06 |
EPS Growth | 34.75% | 17.88% | 25.57% | 53.19% | - | - |
Free Cash Flow | - | -83.8 | 184.5 | -7.2 | 99.5 | 226.91 |
Free Cash Flow Per Share | - | -17.83 | 39.26 | -1.53 | 21.17 | 48.28 |
Dividend Per Share | 6.500 | 6.000 | 5.000 | 3.000 | 3.000 | - |
Dividend Growth | 30.00% | 20.00% | 66.67% | - | - | - |
Gross Margin | 44.59% | 43.11% | 41.50% | 41.21% | 67.73% | 63.61% |
Operating Margin | 22.05% | 19.95% | 20.26% | 20.45% | 18.53% | 8.42% |
Profit Margin | 15.50% | 13.76% | 14.52% | 13.77% | 11.98% | -1.03% |
Free Cash Flow Margin | - | -2.11% | 5.78% | -0.27% | 4.95% | 16.17% |
EBITDA | 1,293 | 1,020 | 779.5 | 643.8 | 489 | 226.98 |
EBITDA Margin | 28.69% | 25.68% | 24.41% | 24.01% | 24.30% | 16.18% |
D&A For EBITDA | 299.3 | 227.9 | 132.7 | 95.5 | 116.1 | 108.79 |
EBIT | 993.8 | 792.1 | 646.8 | 548.3 | 372.9 | 118.19 |
EBIT Margin | 22.05% | 19.95% | 20.26% | 20.45% | 18.53% | 8.42% |
Effective Tax Rate | 23.21% | 22.70% | 25.53% | 25.26% | 25.41% | 125.09% |
Revenue as Reported | 4,550 | 4,022 | 3,243 | 2,697 | 2,025 | 1,406 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.